FALSE000156604400015660442024-11-072024-11-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________________________________________________________________
FORM 8-K
___________________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 7, 2024
___________________________________________________________________________________________________________
VYNE Therapeutics Inc.
(Exact name of registrant as specified in its charter)
___________________________________________________________________________________________________________
Delaware001-3835645-3757789
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification Number)
685 Route 202/206 N., Suite 301
Bridgewater, New Jersey 08807
(Address of principal executive offices, including Zip Code)
(800) 775-7936
(Registrant’s telephone number, including area code)

___________________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Common Stock, $0.0001 par valueVYNEThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02 Results of Operations and Financial Condition.
On November 7, 2024, VYNE Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. The press release is being furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VYNE THERAPEUTICS INC.
Date: November 7, 2024
By:/s/ Mutya Harsch
Mutya Harsch
Chief Legal Officer and General Counsel


Exhibit 99.1

image.jpg
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
•VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025
•Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024

BRIDGEWATER, N.J., November 7, 2024 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and nine months ended September 30, 2024 and provided a business update.

“We continue to make excellent progress in advancing our two InhiBET™ clinical programs VYN201 and VYN202, and believe each product candidate has the potential to be a differentiated, class-leading therapy for immune-mediated diseases,” said David Domzalski, President and Chief Executive Officer of VYNE. “We recently reported positive SAD data from our Phase 1a SAD/MAD trial of oral, BD2-selective BET inhibitor, VYN202, and we anticipate reporting data from the MAD portion of the trial later this quarter. We are encouraged by the strong enrollment in our ongoing Phase 2b trial for VYN201 which we believe underscores the significant unmet need in the treatment of vitiligo. We expect to complete enrollment next month and report topline data mid- next year.”

Recent Pipeline Updates

VYN201, a locally-administered small molecule pan-BD BET inhibitor:
•Phase 2b trial of VYN201 in nonsegmental vitiligo exceeds initial enrollment target and expected to complete enrollment next month. The Phase 2b trial is expected to be fully enrolled in December 2024, with approximately 40 to 50 subjects per arm. The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025.

•The Phase 2b trial (NCT06493578) is a randomized, double-blind, vehicle-controlled trial evaluating the efficacy, safety and pharmacokinetics of once-daily VYN201 gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. Subjects are being randomized equally (1:1:1:1 ratio) across the active drug cohorts or vehicle. Following the 24-week treatment period, subjects who have been randomized in the three dose cohorts will have the option to continue treatment with their respective dose concentrations for an additional 28-week extension. Subjects who have been randomized in the vehicle group during the initial 24-week treatment period will be equally re-randomized into one of the three active dose cohorts for an additional 28 weeks.

VYN202, an oral small molecule BD2-selective inhibitor:
•VYNE expects to report top-line results from the multiple ascending dose (“MAD”) portion of the Phase 1a trial in the fourth quarter of 2024. Data from the single ascending dose (“SAD”) portion of the trial, announced in September 2024, showed that VYN202 was generally well tolerated with no drug related adverse events. Assessment of key pharmacokinetic and pharmacodynamic parameters demonstrated dose dependent drug concentrations of VYN202 in the blood and showed pharmacodynamic impact of VYN202 on key target-engagement and inflammatory biomarkers in whole blood assays, including an inhibitory effect on select inflammatory biomarkers relevant to psoriasis and rheumatoid arthritis.

•Pending successful completion of the Phase 1a trial, VYNE plans to initiate Phase 1b trials in adult subjects with moderate-to-severe plaque psoriasis and moderate-to-severely active rheumatoid arthritis, with top-line results anticipated in the second half of 2025.

1

Financial Results as of and for the Third Quarter Ended September 30, 2024
Cash position. As of September 30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $70.2 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of September 30, 2024 will be sufficient to fund its operations through the end of 2025.
Share count. As of September 30, 2024, VYNE had 14,751,433 shares issued and outstanding, and outstanding pre-funded warrants to purchase 27,842,740 shares of common stock at an exercise price of $0.0001 per share.
Revenues. Revenues totaled $0.1 million for both the quarters ended September 30, 2024 and 2023, respectively, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed the rights to Finacea® foam.

Research and development expenses. VYNE’s research and development expenses for the quarter ended September 30, 2024 were $10.2 million, representing an increase of $6.9 million, or 208.9%, compared to $3.3 million for the quarter ended September 30, 2023. The increase was primarily driven by increased expenses associated with VYNE's ongoing Phase 2b trial of VYN201 in subjects with nonsegmental vitiligo and its ongoing Phase 1a SAD/MAD trial of VYN202 of $5.0 million and $1.7 million, respectively. Both trials were initiated in June 2024. In addition, employee-related expenses increased by $0.3 million following the hiring of additional research and development personnel.
General and administrative expenses. VYNE’s general and administrative expenses for both the quarters ended September 30, 2024 and 2023 were approximately $3.0 million, representing an immaterial change year-over-year.
Net loss. Net loss and net loss per share for the quarter ended September 30, 2024 were $12.2 million and $0.29, respectively, compared to a net loss and net loss per share of $6.6 million and $2.01, respectively, for the comparable period in 2023.

About VYNE Therapeutics Inc.

VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com







2



Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding VYNE's ability to successfully complete its Phase 1a trial of VYN202, future clinical trials of VYN202, the expected enrollment and timing for reporting top-line results from trials of VYN201 and VYN202, VYNE’s projected cash runway, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results from clinical trials of its product candidates; VYNE’s ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2023, and VYNE’s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

Third-party products and company names mentioned herein may be the trademarks of their respective owners.

3

VYNE THERAPEUTICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)
(Unaudited)
September 30,December 31,
20242023
Assets
Current Assets:
Cash and cash equivalents$16,272 $30,620 
Restricted cash47 54 
Investment in marketable securities53,913 62,633 
Prepaid and other current assets3,303 2,656 
Total Current Assets73,535 95,963 
Non-current Assets:
Operating lease right-of-use assets122 207 
Non-current prepaid expenses and other assets2,541 1,515 
Total Non-current Assets2,663 1,722 
Total Assets$76,198 $97,685 
Liabilities and Stockholders’ Equity
Current Liabilities:
Trade payables$3,986 $1,659 
Accrued expenses6,168 4,119 
Employee related obligations1,071 1,645 
Operating lease liabilities123 115 
Other current liabilities1,313 — 
Total Current Liabilities12,661 7,538 
Long-term Liabilities:
Non-current operating lease liabilities— 99 
Other liabilities— 1,313 
Total Long-term Liabilities— 1,412 
Total Liabilities12,661 8,950 
Commitments and Contingencies
Stockholders' Equity:
Preferred stock: $0.0001 par value; 20,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023— — 
Common stock: $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 14,751,433 and 14,098,888 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively1 1 
Additional paid-in capital782,650 780,044 
Accumulated other comprehensive income34 26 
Accumulated deficit(719,148)(691,336)
Total Stockholders' Equity63,537 88,735 
Total Liabilities and Stockholders’ Equity$76,198 $97,685 
4

VYNE THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except per share data)
(Unaudited)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Revenues
Royalty revenues$121 $114 $417 $348 
Total Revenues121 114 417 348 
Operating Expenses:
Research and development10,248 3,318 21,262 13,284 
General and administrative2,964 3,030 10,022 9,490 
Total Operating Expenses13,212 6,348 31,284 22,774 
Operating Loss(13,091)(6,234)(30,867)(22,426)
Other income, net934 163 3,074 706 
Loss from continuing operations before income taxes(12,157)(6,071)(27,793)(21,720)
Income tax expense— — — — 
Loss from continuing operations(12,157)$(6,071)(27,793)(21,720)
Loss from discontinued operations, net of income taxes— (513)(19)(544)
Net Loss$(12,157)$(6,584)$(27,812)$(22,264)
Loss per share from continuing operations, basic and diluted$(0.29)$(1.85)$(0.65)$(6.66)
Income (loss) per share from discontinued operations, basic and diluted$0.00 $(0.16)$0.00 $(0.17)
Loss per share, basic and diluted$(0.29)$(2.01)$(0.65)$(6.82)
Weighted average shares outstanding - basic and diluted42,587 3,282 42,592 3,271 

5
v3.24.3
Document and Entity Information Document
Nov. 07, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 07, 2024
Entity Registrant Name VYNE Therapeutics Inc
Entity Central Index Key 0001566044
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-38356
Entity Tax Identification Number 45-3757789
Entity Address, Address Line One 685 Route 202/206 N., Suite 301
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 800
Local Phone Number 775-7936
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol VYNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
VYNE Therapeutics (NASDAQ:VYNE)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 VYNE Therapeutics 차트를 더 보려면 여기를 클릭.
VYNE Therapeutics (NASDAQ:VYNE)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 VYNE Therapeutics 차트를 더 보려면 여기를 클릭.